Q-omics provides the consensus-scored GLDCP1 profile across patient tissues and cancer cell-line models. GLDCP1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GLDCP1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GLDCP1 RNA expression shows 12,572 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where GLDCP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLDCP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLDCP1 survival associations across molecular data types. GLDCP1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLDCP1 RNA expression–survival associations across cancer types. High GLDCP1 expression shows unfavorable associations in DLBC, LUAD and READ, but favorable associations in KIRC, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GLDCP1 RNA expression.
This table summarizes GLDCP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GLDCP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLDCP1 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in BRCA, LUAD and LUSC. The KIRC box plot shows higher GLDCP1 RNA expression in normal versus tumor tissue (log2 FC = −0.560, t-test p < 0.001).
This table shows molecular features associated with GLDCP1 in patient tissues and cancer cell lines. In patient samples, GLDCP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
